CTLA-4
Cytotoxic T-lymphocyte-associated protein 4; CD152
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also known as CD152, is an inhibitory receptor belonging to the CD28 immunoglobulin subfamily. CTLA-4 is expressed primarily by T cells. The ligands of CTLA-4, CD80 and CD86, are typically found on the surface of antigen-presenting cells and can either bind CD28 or CTLA-4. The interactions of the ligands with CTLA-4 serve to inhibit T cell responses. Because of its dampening effect, CTLA-4 is a crucial regulator of T-cell homeostasis and self-tolerance. The mechanisms by which CTLA-4 exerts its inhibitory function can be categorized as either cell-intrinsic (affects the CTLA-4 expressing T-cell) or cell-extrinsic (affects secondary cells). CTLA-4 is well recognized as a key immune checkpoint and has gained significant momentum as a therapeutic target in the field of autoimmunity and cancer.
All Product Categories
-
CTLA-4 Related Products (41)
Related Products (41)
-
Recombinant Proteins (25)
-
Antibodies (3)
-
Tuvonralimab
0 ImagesSynonyms: PSB-205; QL1706 (iparomlimab/tuvonralimab); PBS105
-
Muzastotug
0 ImagesSynonyms: ADG126Muzastotug is a humanized immunoglobulin G1-kappa, anti-CTLA4 monoclonal antibody. Muzastotug is an immunostimulant and antineoplastic.
-
Quavonlimab
0 ImagesSynonyms: MK-1308Quavonlimab (MK-1308) is a humanized IgG1 monoclonal antibody targeting CTLA-4. As a competitive inhibitor of CTLA-4, Quavonlimab blocks the binding of CTLA-4 to its ligands CD80 and CD86. Quavonlimab increases interferon production, expands and activates T cells, reduces tumor regulatory T cells, inhibits tumor growth, and induces the proliferation of Ki67-positive CD4 and CD8 cells. Quavonlimab can be used in studies related to solid tumors.
-
Sovipostobart
0 ImagesCat. No.: HY-P990080CAS No.: 2649371-19-5Synonyms: BMS-986249Sovipostobart is an immunoglobulin G1-kappa, anti-CTLA-4 human monoclonal antibody with cleavable prodomain. Sovipostobart is an immunostimulant and antineoplastic.
-
Nurulimab
0 ImagesCat. No.: HY-P99760CAS No.: 2168561-20-2Synonyms: BCD-145Nurulimab is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) human monoclonal antibody. Nurulimab binds to CTLA-4 and blocks its interaction with ligands, stimulating T-cell proliferation, cytokine production, and inducing an antitumor immune response. Nurulimab can be used for the research of unresectable or metastatic melanoma and advanced cutaneous melanoma.
-
Vilastobart
0 ImagesSynonyms: XTX101
-
JMW-3B3
0 ImagesCat. No.: HY-P991959JMW-3B3 is a humanized IgG1λ monoclonal antibody targeting CTLA-4. JMW-3B3 selectively binds the unique C-terminal sequence of sCTLA-4 to block its immunoregulatory and immunosuppressive activity without cross-reacting with full-length CTLA-4 receptor. JMW-3B3 enhances cytokine profiles in PBMC cultures responding to lupus autoantigen-derived peptides. JMW-3B3 enhances IFN-γ production in anti-CD3 stimulated PBMC from melanoma patients at low anti-CD3 doses. JMW-3B3 can be used for the research of systemic lupus erythematosus and malignant melanoma.
-
ABA04
0 ImagesCat. No.: HY-P991951ABA04 is an antibody against human CTLA4.
-
BAT4706
0 ImagesCat. No.: HY-P991953
-
REGN4659
0 ImagesCat. No.: HY-P991961REGN4659 is a fully human anti-CTLA-4 monoclonal antibody and IgG1 antibody. REGN4659 binds to the extracellular domain of human and monkey CTLA-4 with high affinity and specificity. REGN4659 blocks CTLA-4 interaction with CD80 and CD86 ligands. REGN4659 significantly suppresses MC38.Ova tumor growth in CTLA-4 knock-in mice.
-
ADU-1604
0 ImagesCat. No.: HY-P991952ADU-1604 is a humanized IgG1 CTLA-4 antibody. ADU-1604 binds to a unique epitope on CTLA-4 and achieves full blockade of both CD80 and CD86 interactions. ADU-1604 enhances human T cell responses. ADU-1604 demonstrates a favorable tolerability profile. ADU-1604 can be used for melanoma research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
-
Anti-CTLA-4/CD152 Antibody (BN13)
0 ImagesCat. No.: HY-P990848Anti-CTLA-4/CD152 Antibody (BN13) is a kind of mouse IgG2a κ chimeric antibody inhibitor, targeting to human CTLA-4/CD152. Anti-CTLA-4/CD152 Antibody (BN13) can neutralize CTLA-4 (cytotoxic T lymphocyte antigen-4) also known as CD152. Anti-CTLA-4/CD152 Antibody (BN13) can be used for the researches of infection and immunology, such as human immunodeficiency virus (HIV).
-
CS2009
0 ImagesCat. No.: HY-P992511CS2009 is a trispecific antibody targeting PD-1, CTLA-4 and VEGFA. CS2009 blocks the interactions of PD-1/PD-L1, CTLA-4/CD80 and VEGFA/VEGFR2, mediates checkpoint inhibition, and suppresses tumor angiogenesis. CS2009 reactivates PD-1/CTLA-4 double-positive tumor-infiltrating T lymphocytes, induces T cell activation, enhances tumor growth inhibition, promotes vascular normalization, improves T lymphocyte infiltration, and converts the immunosuppressive tumor microenvironment into an immunocompetent one. CS2009 can be used for the research of various advanced solid tumors.
-
KD6001
0 ImagesCat. No.: HY-P991566CAS No.: 2983061-18-1KD6001 is a humanized IgG1κ monoclonal antibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC50: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer.
-
Anti-Rat CTLA-4 Antibody (WKH203)
0 ImagesCat. No.: HY-P991775Anti-Rat CTLA-4 Antibody (WKH203) reacts with rat CTLA-4. Anti-Rat CTLA-4 Antibody (WKH203) binds to the CTLA-4 protein disrupts the key signaling mechanisms linked to the suppression of T cell activity, triggering T cells readily and enhancing the immune system’s capacity to identify and eliminate cancer. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977).
-
GIGA-564
0 ImagesCat. No.: HY-P991958GIGA-564 is a fully human anti-CTLA4 IgG1 monoclonal antibody with a Kd of 9.8 nM. GIGA-564 binds to a unique epitope of CTLA-4, mediates FcR-dependent signaling pathways, depletes CTLA-4-highly-expressing regulatory T cells within tumors, and inhibits the proliferation of peripheral regulatory T cells. GIGA-564 exhibits anti-tumor activity in mouse models. GIGA-564 can be used for tumor research.
-
AN02
0 ImagesCat. No.: HY-179228CAS No.: 1246964-08-8AN02 is a derivative of Curcumin (HY-N0005). AN02 inhibits the proliferation and clonogenicity, migration and invasion of ovarian cancer cells. AN02 dose-dependently upregulates the expression of APC and mediates the degradation of CTLA-4 through SMAD4. In the small xenograft model, AN02 significantly inhibits tumor growth and reverses the tumor immune-suppressive microenvironment. AN02, when combined with Ipilimumab (HY-P9901), can enhance efficacy and inhibit epithelial-mesenchymal transition. AN02 can be used for the study of ovarian cancer.
